Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 9

  • Filters activated: Toxicology. Clear all to show 13 items.
1.

Impact of p38 MAP Kinase Inhibitors on LPS-Induced Release of TNF-α in Whole Blood and Primary Cells from Different Species.

Fehr S, Unger A, Schaeffeler E, Herrmann S, Laufer S, Schwab M, Albrecht W.

Cell Physiol Biochem. 2015;36(6):2237-49. doi: 10.1159/000430188. Epub 2015 Jul 24.

2.

Metabolism and excretion of a novel p38 MAP kinase inhibitor pamapimod in healthy male subjects.

Zhang X, Fettner S, Winter E, Masjedizadeh M, Hisoire G.

Int J Clin Pharmacol Ther. 2011 Jun;49(6):345-52.

PMID:
21612741
3.

Discovery of 6-(2,4-difluorophenoxy)-2-[3-hydroxy-1-(2-hydroxyethyl)propylamino]-8-methyl-8H-pyrido[2,3-d]pyrimidin-7-one (pamapimod) and 6-(2,4-difluorophenoxy)-8-methyl-2-(tetrahydro-2H-pyran-4-ylamino)pyrido[2,3-d]pyrimidin-7(8H)-one (R1487) as orally bioavailable and highly selective inhibitors of p38α mitogen-activated protein kinase.

Goldstein DM, Soth M, Gabriel T, Dewdney N, Kuglstatter A, Arzeno H, Chen J, Bingenheimer W, Dalrymple SA, Dunn J, Farrell R, Frauchiger S, La Fargue J, Ghate M, Graves B, Hill RJ, Li F, Litman R, Loe B, McIntosh J, McWeeney D, Papp E, Park J, Reese HF, Roberts RT, Rotstein D, San Pablo B, Sarma K, Stahl M, Sung ML, Suttman RT, Sjogren EB, Tan Y, Trejo A, Welch M, Weller P, Wong BR, Zecic H.

J Med Chem. 2011 Apr 14;54(7):2255-65. doi: 10.1021/jm101423y. Epub 2011 Mar 4.

PMID:
21375264
4.

Differential effects of p38MAP kinase inhibitors on the expression of inflammation-associated genes in primary, interleukin-1beta-stimulated human chondrocytes.

Joos H, Albrecht W, Laufer S, Brenner RE.

Br J Pharmacol. 2010 Jul;160(5):1252-62. doi: 10.1111/j.1476-5381.2010.00760.x.

5.

Kinase inhibitors: a new approach to rheumatoid arthritis treatment.

Cohen S, Fleischmann R.

Curr Opin Rheumatol. 2010 May;22(3):330-5. doi: 10.1097/BOR.0b013e3283378e6f. Review.

PMID:
20164774
6.

A proof-of-concept and drug-drug interaction study of pamapimod, a novel p38 MAP kinase inhibitor, with methotrexate in patients with rheumatoid arthritis.

Zhang X, Huang Y, Navarro MT, Hisoire G, Caulfield JP.

J Clin Pharmacol. 2010 Sep;50(9):1031-8. doi: 10.1177/0091270009357433. Epub 2010 Jan 25.

PMID:
20100913
7.

Efficacy and safety of pamapimod in patients with active rheumatoid arthritis receiving stable methotrexate therapy.

Alten RE, Zerbini C, Jeka S, Irazoque F, Khatib F, Emery P, Bertasso A, Rabbia M, Caulfield JP.

Ann Rheum Dis. 2010 Feb;69(2):364-7. doi: 10.1136/ard.2008.104802. Epub 2009 Apr 8. Erratum in: Ann Rheum Dis. 2011 Aug;70(8):1519.

PMID:
19357113
8.

Evaluation of the efficacy and safety of pamapimod, a p38 MAP kinase inhibitor, in a double-blind, methotrexate-controlled study of patients with active rheumatoid arthritis.

Cohen SB, Cheng TT, Chindalore V, Damjanov N, Burgos-Vargas R, Delora P, Zimany K, Travers H, Caulfield JP.

Arthritis Rheum. 2009 Feb;60(2):335-44. doi: 10.1002/art.24266.

9.

Pamapimod, a novel p38 mitogen-activated protein kinase inhibitor: preclinical analysis of efficacy and selectivity.

Hill RJ, Dabbagh K, Phippard D, Li C, Suttmann RT, Welch M, Papp E, Song KW, Chang KC, Leaffer D, Kim YN, Roberts RT, Zabka TS, Aud D, Dal Porto J, Manning AM, Peng SL, Goldstein DM, Wong BR.

J Pharmacol Exp Ther. 2008 Dec;327(3):610-9. doi: 10.1124/jpet.108.139006. Epub 2008 Sep 5.

PMID:
18776065

Supplemental Content

Loading ...
Support Center